Advancing new drug therapies for unmet medical needs

Advancing new drug therapies for unmet medical needs 2017-08-17T21:46:52+00:00

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Recent news and media

DMX-200 data to be presented at ASN Kidney Week 2017

Dimerix Limited is pleased to announce that a detailed analysis of the data from the DMX-200 Phase 2a clinical trial in [...]

Dimerix in the news following positive Phase 2a trial results in Chronic Kidney Disease

As you may know, Dimerix was pleased to release positive results for our DMX-200 Phase 2a trial in Chronic Kidney Disease [...]

Dimerix Bioshares Presentation

Dimerix CEO Kathy Harrison presented our work on DMX-200 at the 2017 Bioshares Biotech Summit in Queenstown, New Zealand last week. You [...]